Acrivon Therapeutics

ACRV

Market cap $59.1M

1.88 USD

--0.12

At close Updated Nov 7, 4:00 PM EST

Pre-market

After hours

1.91

+0.03

1.6%

1 day

-6%

5 days

-16.81%

1 month

-1.57%

3 months

48.03%

6 months

52.85%

Year to date

-66.96%

1 year

-77.88%

5 years

-88.7%

10 years

-88.7%

About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Employees: 78

Healthcare Biotechnology